Mepolizumab in severe asthma: Added benefit not proven

(Institute for Quality and Efficiency in Health Care) Drug manufacturer deviated from the specifications of the comparator therapy in the direct comparison. The indirect comparison conducted by the manufacturer was unsuitable for an assessment.